MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Author MStranslate

MStranslate

Spinal Cord Lesions & The Risk of Relapse

MStranslate
December 14, 2015
Neuroimaging, Research
Research Summary: Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis The background Magnetic resonance imaging or MRI has become a common tool for the diagnosis of multiple...

Neuroprotection by Novel T Cell Enzyme Inhibitor

MStranslate
December 9, 2015
Research, Treatments
Research Summary: Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo The background Previous studies have shown that immune cells, known as cytotoxic T cells, are critical in the...

Statement on HSCT for MS: Professor Eva Havrdova

MStranslate
December 7, 2015
Research, Stem Cells, Treatments
Professor Eva Havrdova from Charles University in Prague presented at the recent ECTRIMS Congress, where she discussed the use of Hematopoietic Stem Cell Transplantation (HSCT) for the treatment of multiple...

Nr4a1: Is it the Link Between Stress & MS?

MStranslate
December 1, 2015
Lifestyle, Research
The Background Many studies have highlighted a link between stress and multiple sclerosis (MS), including research that has shown that norepinephrine (a regulator of stress) is implicated in the mouse model...
video

Determining the Effectiveness of MS Treatments

MStranslate
November 24, 2015
Social Media, Treatments, Uncategorized
A short video summarising the key findings of a recent paper, titled "Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple...

Safety of Gadolinium-based Contrast Agents for MRI

MStranslate
November 16, 2015
Neuroimaging
The U.S. Food and Drug Administration recently issued a safety communication on the use of gadolinium-based contrast agents for Magnetic Resonance Imaging (MRI).  As this has relevance for many people...
Multiple Sclerosis

Living with Multiple Sclerosis: Reflections

MStranslate
November 2, 2015
Community, Videos
Our new video, "Reflections", features a selection of positive, personal insights from members of the multiple sclerosis (MS) community worldwide. The quotes used have been taken from online news articles,...

Flaxseed Oil Beneficial for People with MS?

MStranslate
October 19, 2015
Lifestyle, Research
4 Comments
In 2013, the team from Overcoming Multiple Sclerosis (OMS) published a paper as part of the HOLISM research study in the International Journal of Neuroscience. This study showed that the consumption of...
MIS416

Clinical Trial: MIS416 for Secondary Progressive MS

MStranslate
October 8, 2015
Clinical Trials, Research
A detailed look at the development of Innate Immunotherapeutics' potential Secondary Progressive MS treatment,...

Environmental Factors & MS-related Genes

MStranslate
September 30, 2015
Genetics, Research
The development of the International MS Genetics Consortium has led to the identification of more than 159 genetic variants that are associated with MS. However, we have to ask how important are these and are...
  1. 23
  2. 24
  3. 25
  4. 26
  5. 27
  6. 28
  7. 29

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.